Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03204188
Title Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Heart, Lung, and Blood Institute (NHLBI)
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Fludarabine + Ibrutinib + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
National Institutes of Health Clinical Center Bethesda Maryland 20892 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field